Kết quả tìm kiếm - Lothar Mueller

  • Đang hiển thị 1 - 4 kết quả của 4
Tinh chỉnh kết quả
  1. 1
    EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

    EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the periopera... Bằng Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, Sandrine Marréaud, Carmela Caballero, Peter Thuss‐Patience, Lothar Mueller, Annelie Elme, Markus Moehler, Uwe M. Martens, Yoon‐Koo Kang, Sun Young Rha, Annemieke Cats, Masanori Tokunaga, Florian Lordick

    Được phát hành 2019
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

    Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society... Bằng Jalid Sehouli, Dirk Stengel, Philipp Harter, Christian Kurzeder, Antje Belau, Thomas Bogenrieder, Susanne Markmann, Sven� Mahner, Lothar Mueller, Ralf Lorenz, A. Nugent, Jochen Wilke, Andreas Kuznik, Gabriele Doering, A. Wischnik, Harald Sommer, H.G. Meerpohl, W. Schroeder, W. Lichtenegger, Guelten Oskay-Oezcelik

    Được phát hành 2010
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

    Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous c... Bằng Markus Moehler, Annett Maderer, Peter Thuss‐Patience, Baruch Brenner, Jens Meiler, Thomas Jens Ettrich, Ralf‐Dieter Hofheinz, S. Al-Batran, Arndt Vogel, Lothar Mueller, Manfred P. Lutz, Florian Lordick, María Alsina, K Borchert, Richard Greil, Wolfgang Eisterer, Arno Schad, Julia Slotta‐Huspenina, Eric Van Cutsem, Sylvie Lorenzen

    Được phát hành 2020
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

    Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell... Bằng Markus Joerger, Joachim von Pawel, Stefanie Kraff, Jürgen R. Fischer, Wilfried Eberhardt, Thomas Gauler, Lothar Mueller, Niels Reinmuth, Martin Reck, Martin Kimmich, F. Mayer, Hans‐Georg Kopp, Dirk Behringer, Yon‐Dschun Ko, Ralf A. Hilger, Max Roessler, Charlotte Kloft, Andrea Henrich, Berta Moritz, Michael Craig Miller, Salvatore J. Salamone, Ulrich Jaehde

    Được phát hành 2016
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: